Hepatitis A Vaccine (Post-exposure prophylaxis)
Treatment for Acute Hepatitis A
Typical Dosage: 0.5mL or 1mL IM, based on age/manufacturer
Effectiveness
95%
Safety Score
88%
Clinical Trials
200
Participants
5M
Comparative Safety Scale(Higher is safer)
Cyanideâ ī¸
Methđ
CigarettesđŦ
Chemoâĸī¸
Alcoholđē
Morphineđ
Antibioticsđ
Tylenolđ
Exerciseđ
Waterđ§
88
DangerousModerateSafe
Treatment Details
Dosage Range
0.5mL or 1mL IM, based on age/manufacturer
Time to Effect
Protection within 2-4 weeks after first dose, some immediate effect as PEP
Treatment Duration
Single dose for PEP, two doses over 6-12 months for long-term immunity
Evidence Quality
HIGHNumber Needed to Treat (NNT)
10(Treat 10 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
100000(Treat 100000 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$50
Monitoring:$800
Side Effect Mgmt:$0
Total Annual:$850
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$40,000/QALY
QALYs Gained
0.08
Outcome-Based Costs
Cost per Responder
$52.63
Comparison vs No prophylaxis
Cost Difference
+$50/year
More expensive
QALY Difference
+0.08 QALYs
Better outcomes
Dominance
No dominance
Prescription Access Economics
Physician Visit Cost
$100/year
Time Cost
$30/year
Travel + wait time
Insurance Admin Cost
$15/year
Prior auth, claims
Rx Price
$50/year
Risk Assessment
Misuse Risk
LOWMissed Diagnosis Risk
LOWHepatitis A Vaccine (Post-exposure prophylaxis) Outcomes
for Acute Hepatitis A
Efficacy Outcomes
Overall Effectiveness
+95%
Response Rate
+95%
Common Side Effects
Injection site pain
+50%
Headache
+15%
Low-grade fever
+10%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov